As of January 2020, these products are available to physicians in the United States to support procedures to treat patients with vascular obstructions.
Zilver® PTX® Leads to Fewer Complications and Shorter Hospital Stays Than Traditional Bypass Surgery
The data, which were gathered from a randomized controlled trial, show that treatment with Zilver PTX results in fewer complications and shorter hospital stays for patients with peripheral artery disease (PAD)
Back in 2000, Cook Korea first opened in the country as a distributor partner, before progressing to direct sales in a gradual transition.
This is the highest level of recommendation from the NICE committee and means that there is enough evidence for surgeons experienced in managing anal fistulas to consider this procedure as a treatment option.
Dr Dake presented new 5-year data on Zilver PTX that Cook Medical gathered from the randomized controlled trial (RCT) performed to obtain FDA approval. Dr Dake was also the global principal investigator for the study.
4/18/19> Cook Medical provides this data to encourage further collaboration with researchers to benefit patients with peripheral arterial disease.
COOK Medical Reports First U.S. Patient Treated with the Recently Approved Zenith® Dissection Endovascular System
3/29/19: The Zenith Dissection Endovascular System provides physicians a less invasive alternative to open surgery for repair of Type B dissections of the descending thoracic aorta. It consists of a proximal stent-graft component and a distal bare stent component.
The Zenith Dissection Endovascular System consists of a proximal stent-graft component and a distal bare stent component, provides physicians a less invasive alternative to open surgery for repair of Type B dissections of the descending thoracic aorta. The device will be available for sale in the U.S. in the coming months.